Keytruda-Inlyta combo under Priority Review for first-line RCC

Merck & Co. Inc. (NYSE:MRK) said FDA accepted and granted Priority Review to its sBLA for Keytruda pembrolizumab plus Inlyta axitinib as a first-line treatment for renal cell carcinoma. Its PDUFA date is June 20.